OmniCAR CD33 & CLL-1 (Prescient Therapeutics)

N/A

Report date: 2025/01/26 16:32:28

Base Information

Drug NameOmniCAR CD33 & CLL-1 (Prescient Therapeutics)
Drug Alias NameCLL1-CD33 cCAR (Prescient Therapeutics)Dual anti-CLL1/anti-CD33 CAR T-cell therapy (Prescient Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionC-Type lectin domain family 12 member A modulatorsMyeloid cell surface antigen CD33 modulators
TargetsC-Type lectin domain family 12 member AMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrescient Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPrescient Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A